Townsquare Capital LLC Sells 4,633 Shares of Thermo Fisher Scientific Inc. $TMO

Townsquare Capital LLC lowered its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 61.0% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,965 shares of the medical research company’s stock after selling 4,633 shares during the quarter. Townsquare Capital LLC’s holdings in Thermo Fisher Scientific were worth $1,438,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also bought and sold shares of the company. Highline Wealth Partners LLC grew its stake in Thermo Fisher Scientific by 126.9% during the third quarter. Highline Wealth Partners LLC now owns 59 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 33 shares in the last quarter. Cloud Capital Management LLC purchased a new position in shares of Thermo Fisher Scientific during the third quarter valued at about $31,000. Capital A Wealth Management LLC lifted its position in shares of Thermo Fisher Scientific by 825.0% in the second quarter. Capital A Wealth Management LLC now owns 74 shares of the medical research company’s stock worth $30,000 after buying an additional 66 shares in the last quarter. HighMark Wealth Management LLC increased its stake in Thermo Fisher Scientific by 140.6% in the 2nd quarter. HighMark Wealth Management LLC now owns 77 shares of the medical research company’s stock worth $31,000 after acquiring an additional 45 shares during the last quarter. Finally, Elevation Wealth Partners LLC raised its holdings in shares of Thermo Fisher Scientific by 35.1% during the 3rd quarter. Elevation Wealth Partners LLC now owns 77 shares of the medical research company’s stock worth $37,000 after acquiring an additional 20 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling

In related news, EVP Michael D. Shafer sold 10,725 shares of the company’s stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $600.00, for a total transaction of $6,435,000.00. Following the completion of the transaction, the executive vice president owned 18,731 shares in the company, valued at $11,238,600. This represents a 36.41% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Lisa P. Britt sold 10,225 shares of the business’s stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $571.62, for a total value of $5,844,814.50. Following the sale, the vice president owned 14,145 shares of the company’s stock, valued at $8,085,564.90. The trade was a 41.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 124,517 shares of company stock valued at $72,363,568 in the last ninety days. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Performance

Shares of TMO opened at $593.16 on Friday. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $643.99. The stock has a fifty day moving average price of $594.14 and a 200-day moving average price of $536.01. The company has a current ratio of 1.50, a quick ratio of 1.11 and a debt-to-equity ratio of 0.62. The firm has a market cap of $222.86 billion, a PE ratio of 34.27, a P/E/G ratio of 3.99 and a beta of 0.91.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, January 29th. The medical research company reported $6.57 earnings per share for the quarter, topping analysts’ consensus estimates of $6.44 by $0.13. The business had revenue of $12.22 billion for the quarter, compared to analyst estimates of $11.95 billion. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific declared that its Board of Directors has authorized a stock repurchase program on Thursday, November 6th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical research company to repurchase up to 2.4% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board believes its stock is undervalued.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, January 15th. Shareholders of record on Monday, December 15th were issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend was Monday, December 15th. Thermo Fisher Scientific’s dividend payout ratio is presently 9.94%.

Wall Street Analyst Weigh In

TMO has been the subject of a number of recent research reports. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Thermo Fisher Scientific in a research note on Thursday, October 23rd. Morgan Stanley upped their price objective on Thermo Fisher Scientific from $656.00 to $670.00 and gave the company an “overweight” rating in a research report on Tuesday, December 2nd. TD Cowen reiterated a “buy” rating on shares of Thermo Fisher Scientific in a report on Wednesday, January 7th. UBS Group raised their price target on Thermo Fisher Scientific from $500.00 to $590.00 and gave the stock a “neutral” rating in a research report on Thursday, October 23rd. Finally, Argus boosted their price objective on Thermo Fisher Scientific from $580.00 to $610.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $626.79.

Key Thermo Fisher Scientific News

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Q4 results beat expectations — adjusted EPS $6.57 vs. consensus ~$6.44 and revenue $12.21B vs. ~$11.95B, showing 7% sales growth and reinforcing demand from pharma and life‑sciences customers. Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Management disclosed potential EPS upside from the Clario deal, which could be accretive and support longer‑term earnings growth if integration goes as planned. Thermo Fisher Scientific Discloses How Much Clario Deal Could Add To Its EPS
• Positive Sentiment: Some analysts remain bullish — William Blair maintained a Buy on TMO, citing resilient organic growth and stabilizing end markets. Thermo Fisher Scientific: Resilient Organic Growth and Stabilizing End-Markets Support Sustained Buy Rating
• Neutral Sentiment: Investor presentation and earnings call provide detail on segment performance, but no near-term catalytic change was signaled beyond the guidance update. Thermo Fisher Scientific Inc. 2025 Q4 – Results – Earnings Call Presentation
• Negative Sentiment: FY2026 guidance came in cautious: EPS $24.220–24.800 (vs. consensus ~24.64) and revenue $46.3B–$47.2B (vs. consensus ~46.5B), implying only 4%–6% growth and modest organic demand — investors focused on the conservative tone. Thermo Fisher stock slides on cautious profit guidance
• Negative Sentiment: Management signaled margin pressure and cautious profit expectations for 2026, which pressured the stock despite the Q4 beat. Thermo Fisher slips after issuing 2026 outlook (update)

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.